...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Arthritis care & research >First‐Line, Non‐Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β 2 2 ‐Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies Tests
【24h】

First‐Line, Non‐Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β 2 2 ‐Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies Tests

机译：一线，非标准抗磷脂抗体试验临床实践中抗磷脂综合征的诊断：抗β22 - 乙醛I结构域I和抗磷脂酰丝氨酸/凝血酶体复合抗体试验的组合

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To assess the value of a combination of anti–β 2 ‐glycoprotein I (anti‐β 2 GPI ) domain I antibody and anti–phosphatidylserine/prothrombin complex (anti‐ PS / PT ) antibody tests for the diagnosis of antiphospholipid syndrome ( APS ). Methods This cross‐sectional study involved a cohort of the patients who visited our clinic from April 2005 to March 2013. Tests for anti‐β 2 GPI domain I antibodies, IgG anti‐ PS / PT antibodies, and IgM anti‐ PS / PT antibodies, together with tests for criteria‐defined antiphospholipid antibodies ( aPL ), were performed in all patients. The total antiphospholipid score ( aPL ‐S) was calculated for each patient according to titers of and positivity for aPL . Results The study enrolled 157 patients (51 patients with APS and 106 with non‐ APS autoimmune diseases). All 21 patients positive for both anti‐β 2 GPI domain I antibodies and IgG and/or IgM (IgG/IgM) anti‐ PS / PT antibodies had APS with a high total aPL ‐S (median 46, range 26–76), as did all of the 10 patients who were positive for anti‐β 2 GPI domain I antibodies but negative for IgG/IgM anti‐ PS / PT antibodies (median 22, range 4–39). Of the 14 patients who were positive for IgG/IgM anti‐ PS / PT antibodies but negative for anti‐β 2 GPI domain I antibodies, 11 (79%) had APS ; these individuals also had high total aPL ‐S values (median 23, range 11–60). In contrast, only 9 of the 112 patients (8%) with none of these antibodies had APS. Conclusion The combination of the IgG anti–β 2 GPI domain I antibody and IgG/IgM anti‐ PS / PT antibody tests shows a high positive predictive value for the diagnosis of APS and a strong correlation with the aPL ‐S. This combination as the first‐line test for aPL may contribute to the simple and definite identification of APS with a high risk of thrombosis in clinical practice.
机译：目的评价抗β2-糖蛋白I（抗β2GPI）结构域I抗体和抗磷脂酰丝氨酸/凝血酶综合体（抗PS / PT）抗体试验的抗磷脂蛋白综合征（APS ）。方法，这种横断面研究涉及从2005年4月到2013年3月访问我们诊所的患者的群组。抗β2GPI结构域I抗体，IgG抗PS / Pt抗体和IgM抗PS / Pt抗体的试验在所有患者中都进行了标准定义的抗磷脂抗体（APL）的测试。根据APL的滴度和阳性的每只患者计算总抗磷脂评分（APL -S）。结果该研究招收了157名患者（51例APS和106例，具有非APS自身免疫疾病）。所有21名抗β2GPI结构域I抗体和IgG和/或IgM（IgG / IgM）抗PS / Pt抗体阳性的患者具有高总APL-S（中位数46，范围26-76），所有10名患者的抗β2GPI结构域I抗体的所有患者都是阳性的，但是IgG / IgM抗PS / Pt抗体的阴性（中值22，范围4-39）。对于IgG / IgM抗PS / Pt抗体阳性的14名患者，但抗β2GPI结构域的阴性为阴性，11（79％）具有AP;这些个体也具有高总APL -S值（中位数23，范围11-60）。相比之下，112名患者中只有9例（8％），没有这些抗体的APS。结论IgG抗β2GPI结构域I抗体和IgG / IgM抗PS / Pt抗体试验的组合显示了对AP的诊断和与APL -S的强烈相关性的高阳性预测值。这种组合作为APL的一线试验可能有助于临床实践中具有高血栓形成风险的APS的简单和明确的鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号